<SEC-DOCUMENT>0000950123-22-000334.txt : 20220421
<SEC-HEADER>0000950123-22-000334.hdr.sgml : 20220421
<ACCEPTANCE-DATETIME>20220119163107
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-22-000334
CONFORMED SUBMISSION TYPE:	DRSLTR
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AN2 Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001880438
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				820606654
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRSLTR

	BUSINESS ADDRESS:	
		STREET 1:		1800 EL CAMINO REAL, SUITE D
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94027
		BUSINESS PHONE:		(650) 331-9090

	MAIL ADDRESS:	
		STREET 1:		1800 EL CAMINO REAL, SUITE D
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94027
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRSLTR
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRSLTR</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g211954g20r19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Josh Seidenfeld </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T:<I>
</I>(650) 843-5862 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jseidenfeld@cooley.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January 19, 2022
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of
Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Life Sciences </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street,
N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Franklin Wyman </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Mary Mast </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Gary Guttenberg </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Christine Westbrook </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AN2 Therapeutics, Inc. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Amendment No.&nbsp;1 to Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Submitted November&nbsp;19, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>CIK No.&nbsp;0001880438 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and
Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of AN2 Therapeutics, Inc. (the &#147;<B><I>Company</I></B>&#148;), the following information is in response to comments received
from the staff (the &#147;<B><I>Staff</I></B>&#148;) of the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) by letter dated December&nbsp;3, 2021 (the &#147;<B><I>Comment Letter</I></B>&#148;) with respect to the
Company&#146;s Amendment to No.&nbsp;1 Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> submitted to the Commission on September&nbsp;24, 2021. Concurrently with the submission of this response letter, the Company is
submitting Amendment No.&nbsp;2 to the Company&#146;s Confidential Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (&#147;<B><I>DRS Amendment No.</I></B><B><I></I></B><B><I>&nbsp;2</I></B>&#148;). In addition to
addressing the comments raised by the Staff in its Comment Letter, the Company has included other revisions and updates to its disclosure in DRS Amendment No.&nbsp;2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the convenience of the Staff, the numbering of the paragraphs below corresponds to the numbering of the comment in the Comment Letter, the text of which
we have incorporated into this response letter for convenience and which is followed by the Company&#146;s response. In the responses below, page number references are to DRS Amendment No.&nbsp;2. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Amendment No.&nbsp;1 to Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> Submitted November&nbsp;19, 2021 </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Prospectus Summary </U></I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Our Solution:
Epetraborole, </U></I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>page 3 </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We note your response and revisions related to prior comment 1. Please also balance your disclosure in this
section with discussion of three clinical trials that were terminated as a result of clinical resistance, as referenced on pages <FONT STYLE="white-space:nowrap">106-107.</FONT> Please also briefly explain clinical resistance in the summary.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley
LLP&nbsp;&nbsp;&nbsp;&nbsp;3175 Hanover Street&nbsp;&nbsp;&nbsp;&nbsp;Palo Alto, CA&nbsp;&nbsp;&nbsp;&nbsp;94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: +1 650 843 5000 f:
+1 650 849 7400 cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g211954g20r19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January 19, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Two </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosures on pages 4 and 5 of DRS Amendment No.&nbsp;2.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations </U></I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Critical Accounting Policies, Significant Judgments and Use of Estimates </U></I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Stock-Based Compensation </U></I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Common Stock
Valuations, page 85 </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Please refer to prior comment 13. Your revised disclosure addresses the specific methodology and key
assumptions used to determine the fair value of your common stock. Please revise to explain how you determined the enterprise value, which as you state on page 85, is allocated across classes and series of capital stock to determine the estimated
fair value of common stock at each valuation date. Please also disclose the nature of the assumptions used in determining the enterprise value. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosures on pages 88 and 89 of DRS Amendment
No.&nbsp;2. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Business </U></I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Prior Clinical
Experience with Epetraborole, </U></I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>page 106 </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We note that you added disclosure stating the observations of clinical resistance were similar to those for
rifampicin. It is inappropriate to imply that you are likely to achieve similar results. Please revise your disclosure accordingly. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosures on page 108 of DRS Amendment No.&nbsp;2 to
remove any implications that the observations of clinical resistance in prior clinical studies of epetraborole were similar to those for rifampicin. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Adjuvant Global Health Agreement, </U></I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>page 115
</U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We note your response to prior comment 17. You state on page 115 that given &#147;substantially all NTM
development activities, including toxicology studies, clinical trials and manufacturing, overlap with tuberculosis and melioidosis development activities, we believe the risk of repayment related to any future potential investment is low.&#148;
Please revise this statement in light of the fact that regulatory strategies, product registration, and seeking funding from governmental grants and other granting sources may not overlap with NTM activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosures on page 118 of DRS Amendment No.&nbsp;2. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley
LLP&nbsp;&nbsp;&nbsp;&nbsp;3175 Hanover Street&nbsp;&nbsp;&nbsp;&nbsp;Palo Alto, CA&nbsp;&nbsp;&nbsp;&nbsp;94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: +1 650 843 5000 f:
+1 650 849 7400 cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g211954g20r19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January 19, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Three </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>License Agreement with Anacor Pharmaceuticals, Inc., </U></I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>page 116 </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We note your response to prior comment 18. Please clarify, if true, that you sublicense to Brii Biosciences
Limited intellectual property licensed from Anacor Pharmaceuticals. Ensure that your revisions clarify the circumstances under which a breach of your agreement by Brii Biosciences could result in a breach of your agreement with Anacor
Pharmaceuticals. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosures on
pages 39, 40, and 120 of DRS Amendment No. 2 to clarify that it licenses to Brii Biosciences Limited certain intellectual property rights from Anacor Pharmaceuticals. The Company also respectfully advises the Staff that a breach of the License
Agreement entered into between the Company and Brii Biosciences Limited will not directly result in a breach of the Company&#146;s agreement with Anacor Pharmaceuticals. The Company has accordingly revised the disclosures on pages 7 and 39 of DRS
Amendment No.&nbsp;2 to remove any such references. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please contact me at (650) 843 5862 with any questions or further comments regarding our responses to the Staff&#146;s comments. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sincerely,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Josh Seidenfeld</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Josh Seidenfeld</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Eric Easom, <I>AN2 Therapeutics, Inc.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Lucy Day, <I>AN2 Therapeutics, Inc.</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Sally Kay, <I>Cooley LLP</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Anitha Anne, <I>Cooley LLP</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Emily Roberts, <I>Davis Polk</I><I></I><I>&nbsp;&amp; Wardwell LLP</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley
LLP&nbsp;&nbsp;&nbsp;&nbsp;3175 Hanover Street&nbsp;&nbsp;&nbsp;&nbsp;Palo Alto, CA&nbsp;&nbsp;&nbsp;&nbsp;94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: +1 650 843 5000 f:
+1 650 849 7400 cooley.com </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g211954g20r19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g211954g20r19.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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H#4,-A<,JGM52BX*O5DZGLZ7-.I5JR;?(FH*G#503?TC7KGY.% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
